Bridget Hindman has more than four years of medical writing experience in the pharmaceutical industry. She has authored and led the development of content for regulatory submissions, manuscripts, and intellectual property documents for pharmaceutical agents including small molecules, cell/gene therapy, and medical devices across oncology, pain, cardiac, neurology, endocrinology, autoimmune, ophthalmology and other indications across all phases of development from first-in-human to registration-enabling Phase III. She has experience in drafting both preclinical and clinical manuscripts and has collaborated and coordinated with investigators across multiple study sites to present data as well as explore potential new treatment paradigms via novel drug combinations. In the regulatory sphere, Bridget has authored multiple successful orphan drug designation requests across different indications, IND submissions, briefing packages for Pre-IND and Type C meetings, CSRs, as well as clinician focused documents including Investigator Brochures and trial protocols.
Before joining Halloran, Bridget was the Director of Intellectual Property and Medical Writing at Arog Pharmaceuticals, where she oversaw all medical writing efforts and was responsible for managing and developing a diverse patent portfolio for a small molecule tyrosine kinase inhibitor in Phase III trials and primarily developed in oncology indications. Before that, she was a Regular Fellow at the National Institute for Occupational Safety and Health working in the Toxicology and Molecular Biology Branch in the field of particulate-related pulmonary toxicology where she was responsible for developing preclinical models and assays.
West Virginia University, Cancer Cell Biology (PhD)
University of Texas at Dallas, Molecular Biology and Criminology (BS)